Skip to main content
. 2023 Sep 27;22:261. doi: 10.1186/s12933-023-01982-6

Table 1.

Characteristics of SCAPIS participants stratified by sex and glycemic status

Men Women
Total Normoglycaemia Pre-diabetes Diabetes Total Normoglycemia Pre-diabetes Diabetes
Sample size -n (%) 14624 10634 (72.7) 2571 (17.6) 1419 (9.7) 15496 12400 (80.0) 2233 (14.4) 863 (5.6)
Sociodemographics
 Age—mean (SD) 57.5 (4.4) 57.1 (4.3) 58.2 (4.3) 59.1 (4.2) 57.5 (4.3) 57.3 (4.3) 58.2 (4.3) 58.8 (4.0)
Education, highest level
  < Compulsory school (%) 100 (0.7) 59 (0.6) 23 (0.9) 19 (1.4) 95 (0.6) 58 (0.5) 26 (1.2) 11 (1.3)
 Compulsory school (%) 1382 (9.9) 1734 (7.7) 497 (10.7) 318 (14.7) 1137 (7.6) 822 (6.8) 217 (10.0) 111 (13.4)
 Upper Secondary Highschool (%) 6798 (48.6) 9971 (44.4) 2268 (48.8) 1083 (50.0) 6350 (42.5) 5075 (41.9) 954 (44.0) 404 (48.9)
 University (%) 5712 (40.8) 10638 (47.7) 1834 (39.5) 733 (33.9) 7344 (49.2) 6170 (50.9) 973 (44.8) 300 (36.3)
History of cardiovascular disease
 Previous MI, CABG or PCI n (%) 541 (3.7) 254 (2.4) 154 (6.0) 129 (9.1) 152 (1.0) 74 (0.6) 37 (1.7) 41 (1.7)
Family history of cardiovascular diseases
 MI, subjects’ parent or sibling n (%) 3589 (26.2) 2561 (25.6) 629 (26.2) 399 (31.7) 4606 (31.5) 3618 (30.7) 702 (33.8) 286 (37.0)
 Stroke subjects’ parent or sibling n (%) 3462 (25.5) 2467 (24.9) 654 (27.4) 332 (26.8) 4300 (29.6) 3428 (29.4) 612 (29.8) 260 (33.2)
Medication
 Antihypertensive agents n (%) 3030 (21.6) 1687 (16.5) 681 (27.7) 662 (49.6) 2733 (18.2) 1829 (15.2) 546 (25.4) 358 (43.6)
 Lipid lowering agents n (%) 1386 (9.9) 640 (6.3) 317 (12.9) 429 (32.2) 911 (6.1) 480 (4.0) 182 (8.5) 249 (30.3)
 Glucose lowering agents (oral only) n (%) 696 (52.3) 378 (46.4)
 Insulin only or insulin + oral treatment 242 (30.4) 121 (25.8)
Anthropometry
 BMI, kg/m2 median (Q1–Q3) 26.9 (24.8–29.6) 26.4 (24.4–28.9) 27.9 (25.6–30.6) 29.3 (26.8–32.7) 25.7 (23.1–29.1) 25.1 (22.8–28.2) 27.7 (24.6–31.6) 30.0 (26.4–34.1)
 Waist Circumference, cm median (Q1–Q3) 99.0 (92.0–106.0) 97.0 (91.0–104.0) 102.0 (96.0–110.0) 106.0 (99.0–115.0) 88.0 (80.0–97.0) 86.0 (79.0–95.0) 94.0 (85.0–103.0) 100.0 (91.0–110.0)
Life style
 Current smoking status
  Current 1191 (11.6) 1191 (11.6) 385 (15.6) 220 (16.5) 1432 (11.9) 1432 (11.9) 353 (16.4) 145 (17.7)
  Ex-smoker (regardless of cessation time) 3302 (32.2) 3302 (32.2) 910 (37.0) 540 (40.4) 4623 (38.5) 4623 (38.5) 875 (40.7) 338 (41.2)
  Never 5764 (56.2) 5764 (56.2) 1167 (47.4) 575 (43.1) 5956 (49.6) 5956 (49.6) 921 (42.9) 337 (41.1)
  Pack-years—median (Q1–Q3) 13.0 (5.5–25.0) 12.0 (5.0–23.3) 15.0 (6.8–27.8) 18.0 (9.3–30.6) 12.0 (5.0–21.5) 11.1 (4.5–20.5) 13.8 (6.0–24.8) 18.5 (9.9–29.3)
 Physical activity (min/day)
  Sedentary median (Q1–Q3) 180 (120–255) 182 (121–253) 187 (127–263) 203 (137–287) 151 (102–217) 151 (103–215) 154 (103–225) 174 (113–249)
  Low-intensity median (Q1–Q3) 330 (272–393) 328 (273–389) 329 (272–394) 309 (254–373) 363 (307–422) 362 (308–423) 370 (309–431) 348 (286–414)
  Moderate- and vigorous median (Q1–Q3) 49.0 (32.0–71.0) 54.0 (37.0–75.0) 52.0 (35.0–73.0) 43.0 (28.0–65.0) 48.0 (32.0–67.0) 51.0 (36.0–70.0) 47.0 (32.0–67.0) 41.0 (26.0–59.0)
Laboratory measurements
 Fasting glucose, mmol/l—mean (SD) 5.7 (1.3) 5.3 (0.5) 6.3 (0.4) 8.3 (2.5) 5.5 (1.0) 5.2 (0.5) 6.2 (0.5) 7.9 (2.4)
 HbA1c, mmol/mol—mean (SD) 36.9 (7.2) 34.8 (3.1) 37.7 (4.0) 51.0 (14.5) 36.3 (5.7) 35.0 (3.0) 38.3 (4.1) 49.3 (14.1)
 HbA1c, % 5.5 5.4 5.6 6.8 5.4 5.4 5.6 6.6
 High sensitivity CRP, mg/L—mean (SD) 2.1 (4.6) 1.9 (3.8) 2.4 (4.5) 3.1 (8.6) 2.2 (4.1) 1.9 (3.7) 3.0 (5.3) 3.5 (4.8)
 Total cholesterol, mmol/L—mean (SD) 5.32 (1.06) 5.45 (1.00) 5.13 (1.06) 4.65 (1.11) 5.64 (1.02) 5.70 (1.00) 5.52 (1.01) 5.08 (1.15)
 HDL, mmol/L—mean (SD) 1.41 (0.40) 1.45 (0.39) 1.37 (0.38) 1.24 (0.37) 1.83 (0.50) 1.88 (0.49) 1.71 (0.45) 1.54 (0.50)
 LDL, mmol/L—mean (SD) 3.43 (0.97) 3.56 (0.93) 3.27 (0.96) 2.84 (1.01) 3.45 (0.96) 3.49 (0.95) 3.39 (0.94) 3.02 (1.07)
 Remnant, mmol/L—mean (SD) 0.47 (0.41) 0.46 (0.40) 0.49 (0.44) 0.57 (0.41) 0.36 (0.34) 0.33 (0.33) 0.43 (0.33) 0.50 (0.38
 Triglycerides, mmol/L—mean (SD) 1.4 (1.0) 1.3 (0.9) 1.4 (1.2) 1.8 (1.4) 1.1 (0.6) 1.1 (0.5) 1.2 (0.7) 1.6 (1.1)
 eGFR ml/min/1,73 m2 mean (SD) 85.3 (11.8) 84.7 (11.5) 85.9 (12.2) 88.3 (13.1) 84.4 (12.4) 84.1 (12.2) 85.2 (12.4) 87.1 (13.9)
 eGFR, ml/min/1,73 m2 < 60 n (%) 299 (2.0) 190 (1.8) 58 (2.3) 51 (3.6) 409 (2.6) 325 (2.6) 54 (2.4) 30 (3.5)
Clinical characteristics
 Diabetes duration, years- mean (SD) 9.3 (9.1) 10.9 (11.7)
 Systolic blood pressure, mmHg—mean (SD) 128.8 (15.6) 127.5 (15.4) 131.4 (15.5) 133.8 (16.1) 123.2 (17.8) 122.2 (17.7) 126.5 (17.7) 129.0 (16.8)
 Diastolic blood pressure, mmHg—mean (SD) 78.5 (10.1) 78.0 (10.2) 79.8 (9.9) 80.2 (9.9) 76.6 (10.8) 76.2 (10.8) 78.3 (10.7) 78.8 (9.9)
 Ankle-brachial index—median (IQR) 1.23 (1.17, 1.29) 1.23 (1.17, 1.29) 1.22 (1.16, 1.28) 1.21 (1.15, 1.27) 1.19 (1.10, 1.24) 1.19 (1.13, 1.26) 1.18 (1.11, 1.24) 1.17 (1.10, 1.24)
 Ankle-brachial index < 0.9 n (%) 49 (0.4) 31 (0.2) 19 (0.4) 27 (1.4) 28 (0.2) 12 (0.1) 9 (0.5) 7 (0.9)
 CACS ≥ 100 2657 (19.1) 1647 (16.1) 552 (21.1) 458 (35.3) 908 (6.1) 590 (4.9) 190 (8.9) 128 (15.9)
 Any carotid plaque (≥ 1 vessel) 8928 (61.6) 6342 (60.0) 1590 (62.6) 996 (71.2) 7536 (49.1) 5888 (47.9) 1153 (52.2) 495 (58.6)